Targeting CPT1A-Induced RAD51 Succinylation Overcomes DNA Repair-Mediated Temozolomide Resistance in Glioblastoma

Background Temozolomide (TMZ) resistance in glioblastoma (GBM) is largely driven by enhanced DNA repair, but the contribution of mitochondrial metabolism and post-translational modifications remains unclear. Methods Integrated multi-omics were performed on TMZ-sensitive and resistant GBM cells. Succinylation sites were mapped by mass spectrometry; the succinyltransferase was identified via co-IP and in vitro assays. Mechanistic studies used mutagenesis, ubiquitination/degradation assays, and homologous recombination (HR) reporters. Pharmacological inhibition and a natural compound disrupting CPT1A–RAD51 were tested in orthotopic xenografts. Clinical relevance was evaluated in two patient cohorts. Results Resistant cells exhibited elevated α-ketoglutarate and succinate, expanding the succinyl-CoA pool. This rewiring drove RAD51 succinylation at K156, catalyzed by CPT1A—a novel succinyltransferase. K156 succinylation antagonized STUB1-dependent K48-linked ubiquitination at K216, protecting RAD51 from degradation and enhancing HR repair. CPT1A inhibition reduced RAD51 succinylation, impaired DNA repair, and restored TMZ sensitivity in vitro and in vivo. A natural compound disrupting the CPT1A–RAD51 interaction potently sensitized GBM to TMZ in vivo. Clinically, elevated RAD51 K156 succinylation correlated with poor prognosis and TMZ resistance. Conclusions We define a metabolic–epigenetic axis—TCA/succinyl-CoA/CPT1A/RAD51 K156 succinylation—that governs DNA repair and chemoresistance in GBM. CPT1A emerges as a therapeutic target, and RAD51 K156 succinylation serves as a promising prognostic biomarker for overcoming TMZ resistance.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11431011/v1
Primary Topic
Glioma Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Targeting CPT1A-Induced RAD51 Succinylation Overcomes DNA Repair-Mediated Temozolomide Resistance in Glioblastoma

Dingding Li, Qiankun Ji, Yingbo Yu, Qianshu Gao et al.
Research Square
Glioma Diagnosis and Treatment
preprint

Targeting CPT1A-Induced RAD51 Succinylation Overcomes DNA Repair-Mediated Temozolomide Resistance in Glioblastoma

Dingding Li, Qiankun Ji, Yingbo Yu, Qianshu Gao, Nannan Du, Zhang Yunke, Junying Liu, Miaoran FU, Xiang Zhou, Zhenzhen Zhang, Chen Liu, Guoyin Li, Shiyan Zhang
preprint en

Abstract

Background Temozolomide (TMZ) resistance in glioblastoma (GBM) is largely driven by enhanced DNA repair, but the contribution of mitochondrial metabolism and post-translational modifications remains unclear. Methods Integrated multi-omics were performed on TMZ-sensitive and resistant GBM cells. Succinylation sites were mapped by mass spectrometry; the succinyltransferase was identified via co-IP and in vitro assays. Mechanistic studies used mutagenesis, ubiquitination/degradation assays, and homologous recombination (HR) reporters. Pharmacological inhibition and a natural compound disrupting CPT1A–RAD51 were tested in orthotopic xenografts. Clinical relevance was evaluated in two patient cohorts. Results Resistant cells exhibited elevated α-ketoglutarate and succinate, expanding the succinyl-CoA pool. This rewiring drove RAD51 succinylation at K156, catalyzed by CPT1A—a novel succinyltransferase. K156 succinylation antagonized STUB1-dependent K48-linked ubiquitination at K216, protecting RAD51 from degradation and enhancing HR repair. CPT1A inhibition reduced RAD51 succinylation, impaired DNA repair, and restored TMZ sensitivity in vitro and in vivo. A natural compound disrupting the CPT1A–RAD51 interaction potently sensitized GBM to TMZ in vivo. Clinically, elevated RAD51 K156 succinylation correlated with poor prognosis and TMZ resistance. Conclusions We define a metabolic–epigenetic axis—TCA/succinyl-CoA/CPT1A/RAD51 K156 succinylation—that governs DNA repair and chemoresistance in GBM. CPT1A emerges as a therapeutic target, and RAD51 K156 succinylation serves as a promising prognostic biomarker for overcoming TMZ resistance.

Research Square
Shanghai Jiao Tong University (CN), Zhoukou Normal University (CN), Fifth Affiliated Hospital of Zhengzhou University (CN), First Affiliated Hospital of Henan University of Traditional Chinese Medicine (CN)
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon